Laimei Pharmaceutical announced that a macrophage CUD005 injection (“CUD005 injection” for short) independently developed by the participating company Sichuan Kangdesai Medical Technology Co., Ltd. to treat decompensated liver cirrhosis has obtained an implied license for drug clinical trials and obtained the “Drug Clinical Trial Approval Notice” approved and issued by the State Drug Administration.
莱美药业：参股公司获得CUD005注射液临床试验批准通知书
Laimei Pharmaceutical: The participating company obtained the CUD005 injection clinical trial approval notice
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.